Fig. 1: Upregulation of SLC26A9 is associated with the development and progression of human CRC as well as a poor prognosis.
From: SLC26A9 promotes colorectal tumorigenesis by modulating Wnt/β-catenin signaling
A SLC26A9 protein expression in adjacent tissues. and CRC tissues was detected by Western blots, *p < 0.05, compared with adjacent tissues, n = 18 in each series. B IHC analysis showed that SLC26A9 is progressively upregulated from adjacent tissues to polyps, adenomas and CRC tissues, with strong expression in the nucleus, cytoplasm and cell membrane of CRC tissues. The left panel shows representative images, and the right panel shows a comparison of SLC26A9 expression levels between groups. **p < 0.01 and &&&&p < 0.0001, compared with adjacent tissues; ^^^^p < 0.0001, compared adenocarcinoma with adenomas groups; ####p < 0.0001, compared adenocarcinoma with hyperplastic polyp groups, scale bars = 25 μm. C, D Upregulation of SLC26A9 in CRC determined by IHC in a tissue microarray is related to a poor prognosis. The left panel shows representative images of SLC26A9 expression in CRC and adjacent tissues. The right panel shows the patient prognosis comparison between groups, scale bars = 25 μm. E ROC analysis of the prognostic sensitivity and specificity for CRC patients and detected by the expression of SLC26A9 in CRC tissues. N adjacent normal, T Tumor, AN adjacent normal, CRC colorectal cancer, Mem Membrane, Cyt Cytoplasm, Nuc nucleus.
